Bioprinting can lower the financial barriers associated with the development of gender-specific medications by streamlining the preclinical research phase. With the ability to quickly test drugs on bioprinted tissues, pharmaceutical companies can reduce the risk of late-stage failures, making the development process more cost-effective.
- Log in or register to contribute
Contribute to three or more articles across any domain to qualify for the Contributor badge. Please check back tomorrow for updates on your progress.